Latest From vasopharm GMBH
Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.
Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.
- Therapeutic Areas
- Neurology, Nervous System
- vasopharm Biotech GMBH
- Western Europe
- Parent & Subsidiaries
- vasopharm GMBH
- Senior Management
Christian Wandersee, CEO
Frank Tegtmeier, PhD, CSO
- Contact Info
Phone: (49) 931 35 90 99-0
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.